BrockNPohlJStekarJ. Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention (II). Comparative study on the uroprotective efficacy of thiols and other sulphur compounds. Eur J Cancer Clin Oncol1981; 17: 1155–63.
2.
Hoefer-JankerWScheefWGunthurUHulsWVahlensiekWBruhlP. Erfahrunger mit der fraktionierten Ifosfamidstosstherapie bei Generalisierten Maligner Tumoren. Med Welt1975; 26: 972–9.
3.
ScheefWSoemerG. Treatment of solid malignant tumours with Holoxan and Uromitexan. Joint Symposium Study Group for Oncology of the German Cancer and Asta-Verke AG, Dusseldorf, 29 February 1980: 21–5.
4.
LangEGoosM. Hypersensitivity to mesna (letter). Lancet1985; 2: 329.
5.
MeanwellCABlakeAELatiefTN, Encephalopathy associated with ifosfamide/mesna therapy. Lancet1985; 1: 406–7.
6.
OsborneRJSlevinML. Ifosfamide, mesna and encephalopathy. Lancet1985; 1: 1398–9.
7.
PinkertonRPhilipTMentignyM Brunat. Ifosfamide, mesna and encephalopathy (letter). Lancet1987; 1: 1399.
8.
PerrenTJTurnerRCSmithIE. Encephalopathy with rapid infusion ifosfamide/mesna. Lancet1987; 1: 390–1.
9.
ShawICGrahamMI. Mesna—a short review. Cancer Treat Rev1987; 14: 67–86.
10.
PinkertonCRPritchardJ. A phase II study of ifosfamide in paediatric solid tumours. Cancer Chemother Pharmacol1989; 24 (suppl): 513–5.
11.
BrockN. Uromitexan (mesna)—concept and mode of action. Beitr Onkol1980; 5: 1–11.
12.
NorpothK. Studies on the metabolism of isophosphamide (NSC-109724) in man. Cancer Treat Rep1976; 60: 4437–43.
13.
OrmstakKUeharaN. Renal transport and disposition of Na/2-mercaptoethanesulphonate disulphide (dimesna) in the rat. FEBS Lett1982; 150: 354–8.
